Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 11 - 19 of 19 items for :

  • "SGLT2 inhibitor" x
Clear All
Ann-Kristin Picke Institute of Comparative Molecular Endocrinology, Ulm University, Ulm, Germany

Search for other papers by Ann-Kristin Picke in
Google Scholar
PubMed Close
,
Graeme Campbell Institute of Biomechanics, TUHH Hamburg University of Technology, Hamburg, Germany

Search for other papers by Graeme Campbell in
Google Scholar
PubMed Close
,
Nicola Napoli Diabetes and Bone Network, Department Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis, Missouri, USA

Search for other papers by Nicola Napoli in
Google Scholar
PubMed Close
,
Lorenz C Hofbauer Department of Medicine III & Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Search for other papers by Lorenz C Hofbauer in
Google Scholar
PubMed Close
, and
Martina Rauner Department of Medicine III & Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Search for other papers by Martina Rauner in
Google Scholar
PubMed Close

2, the key transporter mediating glucose reabsorption by the kidney), thereby increasing urinary glucose excretion ( 164 , 165 ). The first three SGLT2 inhibitors released in the market, namely canagliflozin, empagliflozin and dapagliflozin, have

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0456
Volume/Issue:
Volume 8: Issue 3
Open access
Run-Qing Xiong Department of Ultrasonic Imaging, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Run-Qing Xiong in
Google Scholar
PubMed Close
,
Yan-Ping Li Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Yan-Ping Li in
Google Scholar
PubMed Close
,
Lu-Ping Lin Department of Endocrinology, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Lu-Ping Lin in
Google Scholar
PubMed Close
, and
Jeng-Yuan Yao Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Jeng-Yuan Yao in
Google Scholar
PubMed Close

potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy . Frontiers in Cardiovascular Medicine 2022 9 999254 . ( https://doi.org/10.3389/fcvm.2022.999254 ) 21 Peng M Xia T Zhong Y Zhao M Yue Y Liang L Zhong

Article Type:
Research Article
Collections:
Cardiovascular
DOI:
https://doi.org/10.1530/EC-23-0384
Volume/Issue:
Volume 13: Issue 3
Open access
David Koeckerling Medical Sciences Division, University of Oxford, Oxford, UK

Search for other papers by David Koeckerling in
Google Scholar
PubMed Close
,
Jeremy W Tomlinson Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK

Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed Close
, and
Jeremy F Cobbold Oxford Liver Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Search for other papers by Jeremy F Cobbold in
Google Scholar
PubMed Close

reduction and cardiovascular event incidence ( 91 , 92 ). The safety and efficacy of semaglutide in NAFLD is being investigated in phase II clinical trials. Sodium-glucose transport protein-2 (SGLT-2) inhibitors impede renal glucose reabsorption, serving

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0174
Volume/Issue:
Volume 9: Issue 7
Open access
Aldo Bonaventura Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Aldo Bonaventura in
Google Scholar
PubMed Close
,
Fabrizio Montecucco Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Fabrizio Montecucco in
Google Scholar
PubMed Close
, and
Franco Dallegri Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Franco Dallegri in
Google Scholar
PubMed Close

hypoglycemia (31% lower) (76) . The frequency of hypoglycemia with new GLDs, such as incretins and SGLT2 inhibitors, is very low (77) . Results of some trials indicated the efficacy of dipeptidyl peptidase (DPP)-4 inhibitors in improving glycemic control

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-15-0044
Volume/Issue:
Volume 4: Issue 3
Open access
Chunliang Yang Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
The Center for Biomedical Research, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Chunliang Yang in
Google Scholar
PubMed Close
,
Junyi Li Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Junyi Li in
Google Scholar
PubMed Close
,
Fei Sun The Center for Biomedical Research, Tongji Hospital Research Building, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Fei Sun in
Google Scholar
PubMed Close
,
Haifeng Zhou Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Haifeng Zhou in
Google Scholar
PubMed Close
,
Jia Yang Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Search for other papers by Jia Yang in
Google Scholar
PubMed Close
, and
Chao Yang Department of Gerontology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Wuhan, China

Search for other papers by Chao Yang in
Google Scholar
PubMed Close

enteral glucose absorption (alpha-glucosidase inhibitors) and increasing renal glucose excretion (SGLT-2 inhibitors). When mono-drug therapy fails, various combinations of drug administration are required for different clinical conditions. In worsened

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0225
Volume/Issue:
Volume 9: Issue 7
Open access
Peter Wolf Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Peter Wolf in
Google Scholar
PubMed Close
,
Yvonne Winhofer Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Yvonne Winhofer in
Google Scholar
PubMed Close
,
Martin Krššák Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
High Field MR Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria

Search for other papers by Martin Krššák in
Google Scholar
PubMed Close
, and
Michael Krebs Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Search for other papers by Michael Krebs in
Google Scholar
PubMed Close

. Another question to be addressed in the future is if novel drug approaches for metabolic diseases, such as sodium-glucose-transporter-2 (SGLT-2) inhibitors or glucagon-like-peptide-1 (GLP-1) analogs that improve cardiovascular outcome in patients suffering

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-17-0031
Volume/Issue:
Volume 6: Issue 4
Open access
Iben Rix Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Zealand Pharma A/S, Søborg, Denmark

Search for other papers by Iben Rix in
Google Scholar
PubMed Close
,
Marie L Johansen Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Marie L Johansen in
Google Scholar
PubMed Close
,
Asger Lund Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Asger Lund in
Google Scholar
PubMed Close
,
Malte P Suppli Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Malte P Suppli in
Google Scholar
PubMed Close
,
Elizaveta Chabanova Department of Radiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed Close
,
Gerrit van Hall Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Gerrit van Hall in
Google Scholar
PubMed Close
,
Jens J Holst Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Jens J Holst in
Google Scholar
PubMed Close
,
Nicolai J Wewer Albrechtsen Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed Close
,
Caroline Kistorp Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Caroline Kistorp in
Google Scholar
PubMed Close
, and
Filip K Knop Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Filip K Knop in
Google Scholar
PubMed Close

(2597–3021) 0.91 Diabetes medication, n (%)  Metformin 91 (82.7%) 46 (79.3%) 45 (86.5%) 0.32  SGLT-2 inhibitor 18 (16.4%) 7 (12.1%) 11 (21.2%) 0.20  Sulphonylurea 11 (10.0%) 4 (6.9%) 7 (13.5%) 0

Article Type:
Research Article
Collections:
Metabolic Syndrome and Diabetes
DOI:
https://doi.org/10.1530/EC-23-0161
Volume/Issue:
Volume 13: Issue 1
Open access
Jonathan Hazlehurst Department of Diabetes and Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed Close
,
Bernard Khoo Endocrinology, Division of Medicine, University College London, London, UK

Search for other papers by Bernard Khoo in
Google Scholar
PubMed Close
,
Carolina Brito Lobato Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark

Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed Close
,
Ibiyemi Ilesanmi Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed Close
,
Sally Abbott Department of Dietetics, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK

Search for other papers by Sally Abbott in
Google Scholar
PubMed Close
,
Tin Chan Faculty of Medicine, Chinese University of Hong Kong, Hong Kong

Search for other papers by Tin Chan in
Google Scholar
PubMed Close
,
Sanesh Pillai Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK

Search for other papers by Sanesh Pillai in
Google Scholar
PubMed Close
,
Kate Maslin School of Nursing and Midwifery, University of Plymouth, Plymouth, UK

Search for other papers by Kate Maslin in
Google Scholar
PubMed Close
,
Sanjay Purkayastha Brunel University, London, UK
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK

Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed Close
,
Barbara McGowan Endocrinology, Guys’ and St Thomas’s NHS Foundation Trust, London, UK

Search for other papers by Barbara McGowan in
Google Scholar
PubMed Close
,
Rob Andrews University of Exeter Medical School, Exeter, UK

Search for other papers by Rob Andrews in
Google Scholar
PubMed Close
,
Eveleigh Nicholson Portsmouth Hospitals University NHS Trust, Portsmouth, UK

Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed Close
,
Katherine McCullough Royal Surrey County Hospital, Guildford, UK

Search for other papers by Katherine McCullough in
Google Scholar
PubMed Close
,
Lorraine Albon University Hospitals Sussex NHS Foundation Trust, Worthing, UK

Search for other papers by Lorraine Albon in
Google Scholar
PubMed Close
,
Rachel Batterham Endocrinology, Division of Medicine, University College London, London, UK

Search for other papers by Rachel Batterham in
Google Scholar
PubMed Close
,
Georgios K Dimitriadis King's College Hospital NHS Foundation Trust, London, UK

Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed Close
,
Shareen Forbes BHF Centre for Cardiovascular Science, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK

Search for other papers by Shareen Forbes in
Google Scholar
PubMed Close
,
Gavin Bewick School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

Search for other papers by Gavin Bewick in
Google Scholar
PubMed Close
, and
Tricia M-M Tan Section of Endocrinology and Investigative Medicine, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK

Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed Close

for the latter, but at present, there are no recorded studies or trials of this medication for PBH. In one trial conducted on a small number of people with symptomatic PBH, empagliflozin (a selective SGLT-2 inhibitor) reduced peak postprandial

Article Type:
Other
Collections:
Metabolic Syndrome and Diabetes
DOI:
https://doi.org/10.1530/EC-23-0285
Volume/Issue:
Volume 13: Issue 5
Open access
M Guftar Shaikh Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK
Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK

Search for other papers by M Guftar Shaikh in
Google Scholar
PubMed Close
,
Timothy G Barrett Department of Endocrinology, Birmingham Womens and Children’s Hospital, Birmingham, UK
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

Search for other papers by Timothy G Barrett in
Google Scholar
PubMed Close
,
Nicola Bridges Department of Paediatric Endocrinology, Chelsea and Westminster Hospital, London, UK

Search for other papers by Nicola Bridges in
Google Scholar
PubMed Close
,
Robin Chung Research Working Group, Prader-Willi Syndrome Association, Northampton, UK

Search for other papers by Robin Chung in
Google Scholar
PubMed Close
,
Evelien F Gevers Department of Paediatric Endocrinology, Barts Health NHS Trust, Royal London Hospital, London, UK
Centre for Endocrinology, William Harvey Research Institute, Barts and The London Medical School, Queen Mary University of London, London, UK

Search for other papers by Evelien F Gevers in
Google Scholar
PubMed Close
,
Anthony P Goldstone PsychoNeuroEndocrinologyResearch Group, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK
Department of Endocrinology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK

Search for other papers by Anthony P Goldstone in
Google Scholar
PubMed Close
,
Anthony Holland Department of Psychiatry, University of Cambridge, Cambridge, UK

Search for other papers by Anthony Holland in
Google Scholar
PubMed Close
,
Shankar Kanumakala Royal Alexandra Children’s Hospital, Brighton, UK

Search for other papers by Shankar Kanumakala in
Google Scholar
PubMed Close
,
Ruth Krone Department of Endocrinology, Birmingham Womens and Children’s Hospital, Birmingham, UK

Search for other papers by Ruth Krone in
Google Scholar
PubMed Close
,
Andreas Kyriakou Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK
Department of Paediatric Endocrinology, Makarios Children's Hospital, Nicosia, Cyprus

Search for other papers by Andreas Kyriakou in
Google Scholar
PubMed Close
,
E Anne Livesey Royal Alexandra Children’s Hospital, Brighton, UK
Sussex Community NHS Trust, Brighton, UK

Search for other papers by E Anne Livesey in
Google Scholar
PubMed Close
,
Angela K Lucas-Herald Department of Paediatric Endocrinology, Royal Hospital for Children, Glasgow, UK
Developmental Endocrinology Research Group, University of Glasgow, Glasgow, UK

Search for other papers by Angela K Lucas-Herald in
Google Scholar
PubMed Close
,
Christina Meade CHI at Tallaght University Hospital, Dublin, Republic of Ireland

Search for other papers by Christina Meade in
Google Scholar
PubMed Close
,
Susan Passmore Prader-Willi Syndrome Association, Northampton, UK

Search for other papers by Susan Passmore in
Google Scholar
PubMed Close
,
Edna Roche CHI at Tallaght University Hospital, Dublin, Republic of Ireland
The University of Dublin, Trinity College Dublin, Dublin, Republic of Ireland

Search for other papers by Edna Roche in
Google Scholar
PubMed Close
,
Chris Smith Royal Alexandra Children’s Hospital, Brighton, UK

Search for other papers by Chris Smith in
Google Scholar
PubMed Close
, and
Sarita Soni Learning Disability Psychiatry, NHS Greater Glasgow and Clyde, Glasgow, UK

Search for other papers by Sarita Soni in
Google Scholar
PubMed Close

tirzepatide. Sodium–glucose cotransporter-2 (SGLT-2) inhibitors are often used in adults with T2DM, promoting weight loss as a result of energy loss through increased glycosuria, and are now also recommended for the treatment of T2DM in CA ( 158 ). There have

Article Type:
Other
Collections:
Obesity
DOI:
https://doi.org/10.1530/EC-24-0091
Volume/Issue:
Volume 13: Issue 8
Open access